Alto Neuroscience, Inc. (ANRO)
| Market Cap | 391.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -49.81M |
| Shares Out | 26.96M |
| EPS (ttm) | -3.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 249,417 |
| Open | 14.30 |
| Previous Close | 14.29 |
| Day's Range | 14.24 - 14.70 |
| 52-Week Range | 7.91 - 24.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 33.80 (+132.62%) |
| Earnings Date | Nov 2, 2024 |
About ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ANRO stock is "Strong Buy." The 12-month stock price forecast is $33.8, which is an increase of 132.62% from the latest price.
News
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsych...
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel prec...
Alto Neuroscience to Participate in Upcoming Investor Conferences
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsych...
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate prog...
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsych...
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsych...
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of A...
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and CEO, was named an Entrepreneur Of The Year® 2024 Bay Area Aw...
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place J...
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as...
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress...
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced upcoming data presentations that highlight the company's precision psychiatry pipeline and biomarker-b...
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in devel...
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacod...
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress....
Alto Neuroscience: Potential First-In-Class Approach To Targeting CNS Disorders
Results from phase 2b study, using ALTO-100 for the treatment of patients with Major Depressive Disorder, expected in the 2nd half of 2024. Results from phase 2b study, using ALTO-300 for the treatmen...
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company's board of directors. Dr. Radhakrishnan is ...
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at ...
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the closing of its previously announced upsized initial public offering of 9,246,000 shares of common ...
U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings
Sports equipment and apparel maker Amer Sports priced below the range to raise $1.3 billion at a $6.4 billion market cap. CNS disorder biotech Alto Neuroscience priced its upsized IPO at the top of th...
Alto Neuroscience (ANRO) CEO On IPO & Treating Mental Health
Alto Neuroscience (ANRO) went public on the NYSE today. CEO Amit Etkin joins Nicole Petallides to give an overview of the company.
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public off...
Alto Neuroscience Starts IPO Plan For CNS Disorder Treatments
Alto Neuroscience, Inc. has filed for a $100 million IPO to develop treatments for brain and central nervous system conditions, although the final figure may differ. The company's lead candidate, ALTO...
CNS disorder biotech Alto Neuroscience files for a $100 million IPO
Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Alto Neuroscience IPO Registration Document (S-1)
Alto Neuroscience has filed to go public with an IPO on the New York Stock Exchange (NYSE)